Skip to main content
Clinical Trials/NCT01666405
NCT01666405
Terminated
Phase 1

A Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence

Uroplasty, Inc6 sites in 1 country30 target enrollmentAugust 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Fecal Incontinence
Sponsor
Uroplasty, Inc
Enrollment
30
Locations
6
Primary Endpoint
Effectiveness
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to determine the effectiveness of percutaneous tibial nerve stimulation (PTNS) therapy with the Urgent® PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA) for the treatment of fecal incontinence (FI).

Detailed Description

Pilot Study

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
April 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient history of chronic FI of more than staining for at least 6 months; staining defined as less than the size of a 25¢ piece (quarter)
  • Patient reported and/or failed ≥ 2 conservative therapies (e.g., diet/fiber modification, anti-diarrheal medication, pelvic floor muscle training, biofeedback, medical management, etc.)

Exclusion Criteria

  • Pregnancy or intention to become pregnant during the course of the study
  • Implanted electro-medical device (i.e., pacemaker, defibrillator, deep brain stimulator, etc.)
  • Clinically significant neurological diseases or nerve damage impacting tibial nerve or pelvic floor function
  • Prone to excessive bleeding or bleeding diathesis

Outcomes

Primary Outcomes

Effectiveness

Time Frame: 18 weeks

To assess the effectiveness of PTNS by measuring the proportion of patients with ≥50% decrease in the number of fecal incontinence episodes per week based on the results of the 14-day bowel diary at 18 weeks compared to baseline

Safety

Time Frame: 18 weeks

To characterize adverse events experienced throughout the study

Study Sites (6)

Loading locations...

Similar Trials